We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-21.81%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$222M
AUM Growth
-$100M
Cap. Flow
-$21.8M
Cap. Flow %
-9.81%
Top 10 Hldgs %
58.76%
Holding
56
New
11
Increased
13
Reduced
17
Closed
9

Top Buys

Rank Stock Value
1
TELA icon
TELA Bio
TELA
+$9.68M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.68M
3
CUTR
Cutera, Inc.
CUTR
+$7.8M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$1.98M
5
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
+$1.88M

Top Sells

Rank Stock Value
1
CMRX
Chimerix, Inc.
CMRX
+$14.4M
2
BCYC
Bicycle Therapeutics
BCYC
+$7.68M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.66M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$5.96M
5
CYTK icon
Cytokinetics
CYTK
+$4.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.44B
$24.3M 10.94%
3,332,732
+41,389
+1% +$279K
OCUL icon
2
Ocular Therapeutix
OCUL
$2.38B
$24M 10.83%
5,974,800
– –
CDXS icon
3
Codexis
CDXS
$182M
$13.5M 6.07%
1,288,450
-56,550
-4% -$709K
CRNX icon
4
Crinetics Pharmaceuticals
CRNX
$9B
$12.5M 5.64%
671,300
-21,700
-3% -$433K
CYTK icon
5
Cytokinetics
CYTK
$10.8B
$11.9M 5.36%
302,500
-104,000
-26% -$4.19M
TELA icon
6
TELA Bio
TELA
$29.2M
$11.5M 5.19%
1,643,367
+1,166,367
+245% +$9.68M
TARA icon
7
Protara Therapeutics
TARA
$236M
$8.88M 4%
2,684,167
+10,136
+0.4% +$37.1K
TCON
8
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$8.25M 3.72%
206,266
+48,511
+31% +$1.88M
KNSA icon
9
Kiniksa Pharmaceuticals
KNSA
$6.23B
$7.89M 3.56%
814,250
-298,250
-27% -$2.78M
MRUS
10
DELISTED
Merus
MRUS
$7.65M 3.45%
338,000
– –
KROS icon
11
Keros Therapeutics
KROS
$223M
$7.63M 3.44%
276,000
+10,250
+4% +$450K
INBX
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
$6.7M 3.02%
+590,000
New +$8.68M
ETON icon
13
Eton Pharmaceutcials
ETON
$1.79B
$6.45M 2.91%
2,462,500
+83,225
+3% +$279K
XOMA
14
DELISTED
Xoma
XOMA
$5.86M 2.64%
263,050
-7,950
-3% -$163K
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.58M 2.52%
183,750
-223,252
-55% -$6.66M
CUTR
16
DELISTED
Cutera, Inc.
CUTR
$5.54M 2.5%
+147,700
New +$7.8M
MRSN
17
DELISTED
Mersana Therapeutics
MRSN
$4.84M 2.18%
41,880
+13,480
+47% +$1.27M
PCVX icon
18
Vaxcyte
PCVX
$9.1B
$4.13M 1.86%
190,000
-21,000
-10% -$486K
STXS icon
19
Stereotaxis
STXS
$147M
$3.86M 1.74%
2,099,971
-295,629
-12% -$707K
EWTX icon
20
Edgewise Therapeutics
EWTX
$4.8B
$3.59M 1.62%
451,400
+148,400
+49% +$1.12M
MASS icon
21
908 Devices
MASS
$459M
$3.43M 1.54%
166,406
– –
CMRX
22
DELISTED
Chimerix, Inc.
CMRX
$2.97M 1.34%
1,430,000
-4,473,450
-76% -$14.4M
FBIO icon
23
Fortress Biotech
FBIO
$93.4M
$2.73M 1.23%
216,479
-33,521
-13% -$497K
CLDX icon
24
Celldex Therapeutics
CLDX
$3.18B
$2.43M 1.09%
90,000
-105,500
-54% -$3.06M
LQDA icon
25
Liquidia Corp
LQDA
$6.26B
$2.27M 1.03%
521,500
+342,700
+192% +$1.77M
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2022 Portfolio in Review

As of Q2 2022, Opaleye Management held 56 positions worth $222M, down 31% from $322M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management withdrew a net $21.8M in Q2 2022, closing 9 positions and reducing 17 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $7.68M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Inhibrx, Inc. Common Stock worth $6.7M.

  • Opaleye Management's largest Q2 2022 buy was Inhibrx, Inc. Common Stock: 590,000 shares worth $6.7M.
  • Opaleye Management added most to TELA Bio in Q2 2022, an estimated $9.68M increase.
  • Opaleye Management's biggest Q2 2022 reduction was Chimerix, Inc., cutting an estimated $14.4M.
  • Opaleye Management fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $7.68M.
  • Opaleye Management's ten largest holdings make up 59% of its $222M portfolio in Q2 2022.
  • Opaleye Management opened 11 new positions and closed 9 in Q2 2022.
  • Opaleye Management's portfolio value fell 31% quarter-over-quarter to $222M.

Based on Opaleye Management's 13F filing for Q2 2022, filed 15 Aug 2022.